Medifast (MED) Q4 2025 earnings summary

Executive summary

• Leadership transition announced: CEO to step down in June 2026, with the President expected to assume the role, ensuring continuity in strategy and execution.

• The company is transitioning from a weight loss focus to a broader metabolic health strategy, launching new science-driven products and programs, with a new product line targeting metabolic health and visceral fat reduction to launch in the back half of 2026.

• Coach productivity turned positive year-over-year in Q4 2025 for the first time since 2022, with a 6% increase and revenue per active earning coach rising to $4,664.

• Strong cash position with no debt supports ongoing transformation and coach engagement initiatives.

• Active earning coaches dropped 40.6% to 16,100, but a double-digit percentage achieved executive director rank in Q4, with highest retention since 2022.

Financial highlights

• Q4 2025 revenue was $75.1 million, down 36.9% year-over-year, with full-year 2025 revenue totaling $385.8 million.

• Net loss for Q4 was $18.1 million ($1.65 per diluted share), including a $12.1 million non-cash deferred tax valuation allowance; full-year net loss was $18.7 million ($1.70 per share).

• Gross profit margin for Q4 2025 was 69.4%, down 470 basis points year-over-year, impacted by lower sales and a one-time restructuring charge.

• SG&A expenses decreased 31.5% year-over-year to $59.9 million, but as a percentage of revenue increased to 79.8% due to loss of leverage and restructuring.

• Ended 2025 with $167.3 million in cash and investments, no debt, and working capital at $158.7 million.

Outlook and guidance

• Q1 2026 revenue expected between $65 million and $80 million, with loss per share between $0.15 and $0.70.

• Full-year 2026 revenue guidance of $270 million to $300 million, with loss per share between $1.55 and $2.75.

• Profitability improvements targeted to begin in Q4 2026, following new product launch, with further gains expected into 2027.

• Working capital projected to remain above $140 million at year-end 2026.